191 related articles for article (PubMed ID: 37343519)
41. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G; Cano A; Lederman S; Nappi RE; Santoro N; Wolfman W; English M; Franklin C; Valluri U; Ottery FD
Obstet Gynecol; 2023 Apr; 141(4):737-747. PubMed ID: 36897180
[TBL] [Abstract][Full Text] [Related]
42. Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms.
Hager M; Goldstein T; Fitz V; Ott J
Expert Opin Pharmacother; 2024 May; 25(7):783-789. PubMed ID: 38869992
[TBL] [Abstract][Full Text] [Related]
43. Menopause review: Emerging treatments for menopausal symptoms.
Patel B; S Dhillo W
Best Pract Res Clin Obstet Gynaecol; 2022 May; 81():134-144. PubMed ID: 34965909
[TBL] [Abstract][Full Text] [Related]
44. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
Fraser GL; Obermayer-Pietsch B; Laven J; Griesinger G; Pintiaux A; Timmerman D; Fauser BCJM; Lademacher C; Combalbert J; Hoveyda HR; Ramael S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3519-e3532. PubMed ID: 34000049
[TBL] [Abstract][Full Text] [Related]
45. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.
Zhu D; Chung HF; Dobson AJ; Pandeya N; Anderson DJ; Kuh D; Hardy R; Brunner EJ; Avis NE; Gold EB; El Khoudary SR; Crawford SL; Mishra GD
Am J Obstet Gynecol; 2020 Dec; 223(6):898.e1-898.e16. PubMed ID: 32585222
[TBL] [Abstract][Full Text] [Related]
46. A review of paroxetine for the treatment of vasomotor symptoms.
Slaton RM; Champion MN; Palmore KB
J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
[TBL] [Abstract][Full Text] [Related]
47. Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Tane K; Egawa C; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Kishimoto M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Akazawa K; Miyoshi Y
Breast Cancer; 2017 Jul; 24(4):528-534. PubMed ID: 27730528
[TBL] [Abstract][Full Text] [Related]
48. Identifying meaningful differences in vasomotor symptoms among menopausal women.
Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
[TBL] [Abstract][Full Text] [Related]
49. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
[TBL] [Abstract][Full Text] [Related]
50. ACOG Practice Bulletin No. 141: management of menopausal symptoms.
Obstet Gynecol; 2014 Jan; 123(1):202-216. PubMed ID: 24463691
[TBL] [Abstract][Full Text] [Related]
51. The Effects and Action Mechanisms of Phytoestrogens on Vasomotor Symptoms During Menopausal Transition: Thermoregulatory Mechanism.
Hairi HA; Shuid AN; Ibrahim N'; Jamal JA; Mohamed N; Mohamed IN
Curr Drug Targets; 2019; 20(2):192-200. PubMed ID: 28814228
[TBL] [Abstract][Full Text] [Related]
52. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant.
Douxfils J; Beaudart C; Dogné JM
Lancet; 2023 Nov; 402(10413):1623-1625. PubMed ID: 37865107
[No Abstract] [Full Text] [Related]
53. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis.
Shan D; Zou L; Liu X; Shen Y; Cai Y; Zhang J
Am J Obstet Gynecol; 2020 Jun; 222(6):564-579.e12. PubMed ID: 31870736
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.
Sun Z; Hao Y; Zhang M
Gynecol Obstet Invest; 2013; 75(4):255-62. PubMed ID: 23548358
[TBL] [Abstract][Full Text] [Related]
55. Effect of omega-3 supplements on vasomotor symptoms in menopausal women: A systematic review and meta-analysis.
Mohammady M; Janani L; Jahanfar S; Mousavi MS
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():295-302. PubMed ID: 30056356
[TBL] [Abstract][Full Text] [Related]
56. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.
Wright AC; Beaudoin FL; McQueen RB; Yeung K; Moradi A; Herron-Smith S; Gutierrez E; Lin GA; Pearson SD
J Manag Care Spec Pharm; 2023 Jun; 29(6):692-698. PubMed ID: 37276043
[No Abstract] [Full Text] [Related]
57. Menopause.
Carter AE; Merriam S
Med Clin North Am; 2023 Mar; 107(2):199-212. PubMed ID: 36759091
[TBL] [Abstract][Full Text] [Related]
58. Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause.
Conklin M; Santoro N
Ther Adv Reprod Health; 2023; 17():26334941231177611. PubMed ID: 37388717
[TBL] [Abstract][Full Text] [Related]
59. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.
Stubbs C; Mattingly L; Crawford SA; Wickersham EA; Brockhaus JL; McCarthy LH
J Okla State Med Assoc; 2017 May; 110(5):272-274. PubMed ID: 28649145
[TBL] [Abstract][Full Text] [Related]
60. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Pinkerton JV; Constantine G; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
